Management of acute attacks of hereditary angioedema: potential role of icatibant

Hilary J Longhurst
Department of Immunology, Barts and The London NHS Trust, London, UK

Abstract: Icatibant (Firazyr®) is a novel subcutaneous treatment recently licensed in the European Union for acute hereditary angioedema. Hereditary angioedema, resulting from inherited partial C1 inhibitor deficiency, is a disabling condition characterized by intermittent episodes of bradykinin-mediated angioedema. Icatibant blocks bradykinin B2 receptors, attenuating the episode. Randomized double-blind, placebo-controlled trials of icatibant, showed significant superiority over oral tranexamic acid in 74 European patients and a trend to improvement in a similar US trial comparing icatibant with placebo in 55 patients. Outcomes for several endpoints did not reach significance in the US trial, perhaps because of low participant numbers and confounding factors: a further trial is planned. Open label studies have shown benefit in multiple treatments for attacks at all sites. Approximately 10% of patients require a second dose for re-emergent symptoms, usually 10 to 27 hours after the initial treatment. Its subcutaneous route of administration, good tolerability and novel mode of action make icatibant a promising addition to the limited repertoire of treatments for hereditary angioedema.

Keywords: hereditary angioedema, bradykinin, icatibant, C1 inhibitor deficiency

Hereditary angioedema: clinical features and current management of acute attacks

Hereditary angioedema (HAE) is an autosomal dominant disorder resulting from a partial deficiency of C1 inhibitor (C1-INH). Those affected experience intermittent cutaneous or mucosal swellings or ‘attacks’, lasting between 1 and 5 days.1,2 Swellings affecting the skin are typically painless but may cause disfigurement, or difficulty driving or operating machinery if hands or feet are involved. Cutaneous swelling of the genital area may occasionally lead to retention of urine. Intra-abdominal edema, affecting bowel segments or viscera, is usually very painful, may be associated with vomiting and/or diarrhea, is occasionally mistaken for a surgical emergency and typically leads to temporary disablement, with full recovery after several days.3,4 By contrast, laryngeal attacks may be fatal. Lifetime fatality rates have been estimated at between 10% and 30%6 and 25% of families surveyed in the European HAE register reported an HAE-related fatality, almost exclusively caused by laryngeal edema.6,7 Because the episode fatality rate of laryngeal edema is relatively low, patients may experience many such attacks which resolve spontaneously or with treatment, and therefore may fail to treat laryngeal symptoms as a medical emergency. Conversely patients may be so fearful of laryngeal swelling that they are unwilling to risk being unable to obtain emergency treatment by traveling any distance from their local hospital, resulting in social and employment difficulties.
Prophylaxis for HAE attacks is available; either with attenuated androgens which increase hepatic production of endogenous C1 inhibitor, or by antifibrinolytics such as tranexamic acid or ε-aminocaproic acid (EACA) which may exert a C1-INH sparing effect.9,10 However, efficacy of these agents is variable and most patients continue to experience intermittent swellings albeit at a reduced frequency. Attenuated androgens are associated with androgenic side-effects such as amenorrhea, weight gain, mood changes or hirsutism; and hepatitis or the development of adenomas.9,11,12 Therefore many patients find prophylactic agents insufficiently effective or have unacceptable side-effects.

For acute HAE attacks, tranexamic acid is of very limited benefit and attenuated androgens are not effective. Until recently, C1-INH has been the sole option for acute treatment. C1-INH is purified from the pooled plasma of volunteer donors and is subject to one or more additional treatments to minimize risk of pathogen transmission. Current C1-INH concentrates have proven safe and effective in double-blind placebo-controlled trials9,13–18 and in clinical practice14,19–22 were not predicted by these preclinical studies. Icatibant is rapidly absorbed after subcutaneous administration, although pharmacokinetics were not predicted by these preclinical studies. Icatibant is a synthetic decapeptide and competitive inhibitor of bradykinin B2 receptors. It exerts its action in HAE by antagonizing the vasodilatory effect of excess bradykinin.

**Chemistry**

The active decapeptide of icatibant; H-D-Arg-Arg-Pro-Hyp-Gly-Thi-Ser-D-Tic-Oic-Arg-OH is synthesized in a solid phase peptide synthesis process. Thus, unlike C1 inhibitor, it does not contain human or other animal material. Icatibant is stable for up to 24 months at 5°C, and for up to 6 months at 25°C. This relatively long shelf life is important; current advice is that patients should keep at least one acute treatment at home and the majority of patients require only infrequent treatments.38,39 It is supplied as a 3 mL pre-filled syringe for subcutaneous injection.40

**Pharmacokinetics**

Icatibant is a specific competitive antagonist with similar affinity to bradykinin (1–10 nM) for the B2 receptor, while affinity for the B1 receptor is 100-fold lower. In vitro studies did not reveal activity on other receptors or enzymes, including the cytochrome p450 system, thus major drug interactions were not predicted by these preclinical studies. Icatibant is rapidly absorbed after subcutaneous administration, although individuals may show variation in its absorption rate of up to 25%. Maximum concentrations are reached within 30 minutes and bioavailability is high at around 97%.40,41
Relatively fast absorption is essential since rapid symptom control is required. Intravenous administration was investigated but did not offer pharmacokinetic benefit and was less convenient than subcutaneous injection. Icatibant has low protein binding at around 44% and the volume of distribution is 20 to 25 L, consistent with distribution to include sites of swelling. Animal studies indicate that icatibant is poorly distributed into adipose tissue and does not appear to cross the blood brain barrier. However, it does cross the placenta and is excreted in breast milk in rats.

Icatibant is metabolized in the liver by cleavage to 2 smaller peptides; metabolites (90%) and intact icatibant (10%) are excreted via the kidney. Half-life of icatibant and its metabolites is 1 to 2 hours. Pharmacokinetics appears unaffected by liver and renal impairment in animal studies. Human studies of icatibant, for resistant ascites in patients with cirrhosis of the liver, some of whom had concomitant renal impairment did not raise safety concerns. Icatibant pharmacokinetics do not appear to depend on weight or gender but clearance is reduced in the elderly with area under the curve increased by 5% to 60% in an 80-year-old compared with a 40-year-old patient.

**Pharmacodynamics**

Bradykinin inhibition studies with healthy human volunteers showed a mean EC50 (concentration at which 50% of the measured effect of bradykinin was inhibited) of 7.3 to 10.8 nm depending on the method used. Based on these preclinical data and the results of an open label trial (discussed later) 30 mg was selected as the optimum subcutaneous dose. Since the duration of action of icatibant appeared relatively independent of dose within the therapeutic range, administration of a second (and third) 30 mg dose when indicated appeared more logical than use of a higher single dose.

In rodents, partial bradykinin agonist activity was apparent at supra-therapeutic doses of 3.2 mg/kg or higher. Concentrations sufficient to produce these effects may occur locally and may account for local reactions after subcutaneous injection. Except in the case of overdose, they are otherwise unlikely to occur in clinical use.

**Clinical data**

One pilot unblinded and 2 double-blinded studies have been completed. Patients taking part in the double-blind studies were treated for subsequent attacks with open label icatibant.

The phase II open label dose finding study involved 20 attacks in 15 patients, treated with single intravenous (iv) infusions or subcutaneous (sc) injections (0.4 mg/kg over 30 minutes or 2 hours; or 0.8 mg/kg [iv] over 30 minutes; or 30/45 mg [sc]).

The phase III trials were randomized, double-blinded trials comparing a single 30 mg sc dose of icatibant with placebo (For Angioedema, Subcutaneous Treatment (FAST)-1; US, Canada, Argentina, and Australia) in 56 patients; or the active comparator, tranexamic acid (FAST-2; EU and Israel) in 74 patients. An additional 10 patients with laryngeal edema were treated with open label icatibant. One further patient in the US study experiencing onset of laryngeal symptoms after treatment with placebo was given rescue treatment with icatibant. The phase III studies included open label phase extensions for treated patients and for those enrolled but not treated prior to the end of the double-blind phase.

In all trials, outcomes were measured using a 100 mm visual analog scale (VAS, detailed in Figure 1) reported by the patient for the main, and (in the phase II studies) secondary symptoms. In the phase III studies, additional outcome assessments were made by patient and physician, using a 5 or 7 point symptom score for individual HAE-related symptoms and global wellbeing respectively.

In the phase II study, patients with a variety of peripheral or abdominal attacks were treated at between 6 and 10 hours after the onset of symptoms. Results suggested that subcutaneous administration of icatibant was at least as effective as intravenous, with median time to first response of around 1 hour (iv) or 30 minutes (sc); 30% improvement (time to onset of resolution; TOR30) at 2 to 5 hours and almost complete (90%) resolution (TOR90) at around 8.5 to 16 hours. No clear differences were seen over the dose range tested. On this basis, 30 mg sc was selected for further study.

Both phase III studies included adults (≥18 years) with HAE, experiencing a moderate or severe attack at any site. Study treatment was administered within 6 hours of the attack becoming moderate in severity (≥3/10 on the VAS scale). Those with laryngeal symptoms were treated with icatibant on an open label basis, while those with attacks at other sites (the majority) were randomized to 30 mg icatibant subcutaneously into the anterior abdominal wall, or comparator (oral tranexamic acid 1 g 3 times daily for 3 days in FAST-2; placebo in FAST-1) in a double-blind fashion. The primary endpoint was the time to onset of symptom relief, as measured by sustained improvement of at least 30% on the VAS scale (TOR30), assessed for the principal symptom (for example cutaneous swelling or abdominal pain). Secondary endpoints were response rate at 4 hours...
after treatment, time to relief of secondary symptoms, time to start of improvement according to patient, time to observable regression of visible swelling, global assessment and overall patient improvement and, at week 24, a patient satisfaction questionnaire.

In both studies, patients improved more quickly with icatibant, with a median time to onset of symptom relief (TOR30) of 2.0 hours compared with 12.0 hours for tranexamic acid (FAST -2) and 2.5 compared with 4.6 hours for placebo (FAST-1). The difference was statistically significant for FAST -2 but not for FAST -1. Improvement of the secondary endpoints was faster in the icatibant treated groups. The improvement was significant for the majority of endpoints in FAST -2 but not FAST -1, where parameters showed a non-significant trend to improvement.

Figure 1 shows the mean VAS values over time for the symptom used for the primary endpoint.

**Rescue medication**

More rescue medication, including narcotic and other painkillers, was administered to patients who received placebo or tranexamic acid compared with those who received icatibant. In FAST-1, 11 patients randomized to placebo required rescue medication within 12 hours and a further 14 required rescue medication within 48 hours, compared with 3 patients in 12 hours and 6 within 48 hours for patients receiving icatibant. Similarly in FAST-2, 5 patients randomized to tranexamic acid required rescue medication within 12 hours and 11 required rescue medication within 48 hours, compared with 0 patients in 12 hours and 5 within 48 hours for patients receiving icatibant. The need for additional rescue medication suggests inferior symptom control in the comparator arm, and conversely may have contributed to the lack of significance ($P > 0.05$) in some parameters of the FAST-1 trial.

**Open label treatments**

Data are available on a further 118 patients experiencing 597 HAE attacks treated with icatibant in the open label extensions of FAST-1 and FAST-2. Of these, 59 (9.9%) patients’ symptoms recurred, all but 3 patients more than 10 hours after icatibant administration. Of these patients 60.9% were treated with a further injection of icatibant. Four patients (0.7% of the original group) were treated with a third injection of icatibant.

More recently Malbrán et al have described their experience of treating 163 attacks in 19 patients in Argentina. Time to subjective improvement was an average of 37.9 minutes. One of 102 patients analyzed received a second dose because of insufficient response at 6 hours, 13 of 102 (12.7%) reported an exacerbation of symptoms within 48 hours, of whom 6 received a second dose of icatibant with relief. Similarly, Reshef et al report mean (SE) times to response for 40.6 (18.3) minutes for 25 abdominal attacks and 57.7 (26.4) minutes for 38 cutaneous attacks in 15 patients.

**Laryngeal attacks**

A total of 61 laryngeal attacks of all severities, in 36 patients, have been treated during the FAST trials, including the open label extensions. Time to first symptom improvement...
according to the patient ranged from 0.3 to 3.6 hours (FAST-2) and 0.3 to 2.4 hours (FAST-1). Requirement for a second icatibant injection appeared similar to that required for attacks at other sites at 10% (5 of 50 eligible attacks). One patient with laryngeal edema required intubation 5 minutes after the administration of icatibant.40 However, neither icatibant nor replacement therapy with C1 inhibitor concentrate would be expected to take effect within this timescale. Although not directly comparable, response time seems similar to that reported for C1 inhibitor treatment, although recurrent angioedema seems to be less frequent with C1 inhibitor.18,19

### Multiple attacks

Efficacy of icatibant appears similar in patients receiving up to 110 repeated treatments for multiple attacks. For each attack, the requirement for a second or third dose of icatibant remained constant at around 10% or 1% respectively. There is no method for measuring icatibant antibodies but the low antigenic potential in animal studies (as seen with other short peptides) and the multiple treatment data provide some reassurance that this is unlikely to be a major problem.40

### Recurrent attacks

The observed need for more than one injection in 10% is potentially of concern. Recurrent attacks are likely to be a consequence of the short half-life of icatibant, although continuing overactivation of other inflammatory pathways controlled by C1 inhibitor may contribute. Further information on recurrent attacks is available from Bork’s dose-finding study. Of the 20 HAE attacks, 5 attacks in 4 patients recurred between 14 and 27 hours after the initial treatment, albeit not all treatments were at optimal dose or route. Four attacks recurred at the same site and one at a different site. All were mild and were treated with C1 inhibitor.42 These observations are similar to experience in UK, where recurrence generally occurs the following day and is of slow onset, usually at the same site. We have observed that recurrence appears much more likely in patients with very frequent attacks.48 Thus, it is important that patients are aware of the possibility of recurrence and have a plan for this eventuality.

### Side effects

#### Injection site reactions

Most patients receiving subcutaneous icatibant experience injection site reactions. Erythema, swelling and pain at the injection site lasted from 10 minutes to several hours. However, the reactions are generally tolerated well without need for additional analgesia.42,48 These symptoms are most likely caused by partial agonist activity.

#### Systemic reactions

In clinical studies, the majority of the adverse events appeared to be related to the HAE. A total of 1002 subjects have received icatibant, by the intravenous, subcutaneous, intranasal, inhalational or intra-articular routes, in trials for a variety of indications, with adverse reaction rate (excluding local reactions) similar to placebo.40

Bradykinin is important in protecting ischemic tissues; animal models suggesting poorer outcomes in myocardial ischemia/infarction after icatibant treatment. For this reason icatibant is not recommended for use in the presence of acute cardiac or brain ischemia. Bradykinin antagonism might be expected to increase blood pressure. However, no hypertensive effect at therapeutic doses was seen in clinical or animal trials. Because of icatibant’s short half-life and intermittent use, it would be unlikely to exert a chronic hypertensive effect.

Icatibant has been used in a trial for resistant ascites in liver cirrhosis, which included participants with severe liver and renal impairment, appearing well tolerated in this vulnerable group.40

### Discussion

Icatibant is the first new treatment to be made available for HAE since the advent of C1 inhibitor over 25 years ago,
and is a very welcome addition to the limited therapeutic options available for this disorder. It has not yet been formally evaluated in other bradykinin-mediated angioedemas. However, it would be a logical choice in acquired angioedema due to C1 inhibitor deficiency, especially where large doses of C1 inhibitor would otherwise be required. It could potentially be of use in angiotensin converting enzyme (ACE) inhibitor-related swelling, and in HAE3, which in some cases at least, is associated with factor XII mutations and consequent bradykinin overproduction, although it has not been tested for these indications. Other medications in development for HAE include ecallantide (DX88), a kallikrein inhibitor. Like icatibant, it has the advantage of subcutaneous administration and has shown promise in placebo controlled trials. Ecallantide inhibits kallikrein, thus reducing bradykinin production and preventing further swelling. It is currently unlicensed. Rhucin, a recombinant C1 inhibitor, given intravenously, is also currently unlicensed.

There have been no head-to-head trials comparing icatibant with C1 inhibitor concentrate, or other acute treatments. Studies of emergency treatment where patients need to travel, sometimes for several hours, to get treatment in the trial center are logistically difficult. This, together with the low prevalence of HAE, makes it unlikely that such trials will ever take place. While not being directly comparable, results of studies of C1 inhibitor in acute HAE suggest that the icatibant and C1 inhibitor are broadly similar in terms of onset of relief and time to complete resolution of symptoms.

In the European (FAST-2) trial, icatibant showed a significant benefit compared with tranexamic acid. By contrast, while showing a marked trend in favor of icatibant in the US (FAST-1) trial, the difference between icatibant and placebo did not reach significance for several endpoints, including the primary end point. This is likely to result from underpowering, since the low numbers were randomized for a treatment where delayed and variable responses are expected, and where the outcome measures are subjective. Additionally the use of intravenous rehydration, pain relief – including with opiates – and other symptomatic measures was greater in the placebo group. These almost certainly contributed to the greater than expected improvement in the placebo group, which was of sufficient magnitude to reach the endpoint of 30% improvement in several cases. The ongoing FAST-3 trial will provide additional efficacy data.

Icatibant, with a half-life of around 2 hours, is short-acting compared to C1 inhibitor (half-life 30–64 hours), and to the duration of a typical acute attack, which is 1 to 5 days. This is the likely explanation for recurrent swellings. In practice, recurrence appears a relatively unusual event with only around 10% of attacks requiring more than 1, and 1% requiring more than 2 injections. Since icatibant does not replace C1 inhibitor, attenuate contact pathway or complement activation, or reduce bradykinin production, this may at first appear surprising. Icatibant stops the progression of edema, and allows physiological resolution. Edema may recur if the effect of icatibant wears off while bradykinin levels are still elevated. However, the recurrent edema will often be subclinical since fluid accumulated does not reach a sufficient volume to produce symptoms before natural resolution of the attack.

Treatment of acute HAE with C1 inhibitor is most effective when given early. However, C1 inhibitor’s intravenous route of administration can result in delays in gaining access to treatment. This has been partially addressed by the development of home therapy/self administration programs. Self-administration of C1 inhibitor requires a high degree of patient motivation and support, and the majority of patients who have only infrequent attacks may be less motivated to undergo the necessary training. This is important, since failure to access emergency treatment in a timely manner is the major contributor to the employment, educational and social difficulties associated with HAE, as well as to mortality. The availability of a licensed subcutaneous treatment will facilitate administration by local and community-based healthcare staff without requirement for up to date intravenous skills. Assuming the reassuring safety record of icatibant is confirmed in clinical use, the true place for icatibant seems likely to be in self-administration, where it has potential to address a significant unmet need. In this respect, it may have an advantage over ecallantide, which has been associated with anaphylactoid-like symptoms.

Home therapy programmes for children are less well established, perhaps due to the lower frequency of acute attacks prior to adolescence or anticipated greater technical difficulties with intravenous access. There is a lack of effective prophylactic options for children since attenuated androgens are not recommended pre-puberty. For the few children who have frequent attacks, a subcutaneous acute treatment would be an attractive option, although the pain associated with icatibant injections may be a problem. Repeated doses of icatibant administered to juvenile animals resulted in reversible delay in sexual maturation. Further information would be necessary before icatibant could be recommended for trials in this age group.
Attenuated androgens are contraindicated in pregnancy. Therefore many pregnant women experience an increased frequency of attacks because of lack of effective oral prophylaxis and hormonal changes. Animal studies have shown that icatibant does not appear to have genetic toxicity nor cause structural damage to embryos. No human data are available and therefore C1 inhibitor concentrate, for attacks or prophylactically, must remain the treatment of choice for this difficult to treat group.

Despite only recently gaining a licence in many EU countries and in the US, C1 inhibitor has been used extensively for HAE and has an impressive record. It seems likely that both C1 inhibitor and icatibant will be used, perhaps at different times in the same patient, according to circumstances. The advent of a second, complementary treatment option is a major step forward for this orphan disease.

**Disclosure**

Dr Hilary J Longhurst and department colleagues have received sponsorship for educational purposes, have been paid for providing consultancy services, and have taken part in clinical trials sponsored by Jerini/Shire, CSL, Dyax, and Pharming.

**References**
